journal
https://read.qxmd.com/read/38718321/development-and-implementation-of-a-digital-quality-measure-of-emergency-cancer-diagnosis
#21
JOURNAL ARTICLE
Paarth Kapadia, Andrew J Zimolzak, Divvy K Upadhyay, Saritha Korukonda, Riyaa Murugaesh Rekha, Umair Mushtaq, Usman Mir, Daniel R Murphy, Alexis Offner, Gary A Abel, Georgios Lyratzopoulos, Luke T A Mounce, Hardeep Singh
PURPOSE: Missed and delayed cancer diagnoses are common, harmful, and often preventable. Automated measures of quality of cancer diagnosis are lacking but could identify gaps and guide interventions. We developed and implemented a digital quality measure (dQM) of cancer emergency presentation (EP) using electronic health record databases of two health systems and characterized the measure's association with missed opportunities for diagnosis (MODs) and mortality. METHODS: On the basis of literature and expert input, we defined EP as a new cancer diagnosis within 30 days after emergency department or inpatient visit...
May 8, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38710003/capecitabine-or-capecitabine-plus-oxaliplatin-versus-fluorouracil-plus-cisplatin-in-definitive-concurrent-chemoradiotherapy-for-locally-advanced-esophageal-squamous-cell-carcinoma-crtcoesc-a-multicenter-randomized-open-label-phase-3-trial
#22
JOURNAL ARTICLE
Ruinuo Jia, Tanyou Shan, Anping Zheng, Yaowen Zhang, Ping Lu, Guifang Zhang, Feng Wang, Zhiqiao Xu, Guobao Zheng, Dongxia Tang, Weiguo Zhang, Wanying Li, Ruonan Li, Yibo Guo, Lina Liu, Xiaoyong Luo, Yingjuan Zheng, Zhiwei Chang, Qiming Wang, Xinshuai Wang, Xiaozhi Yuan, Guoqiang Kong, Shuoguo Li, Ruina Yang, Dan Zhou, Jing Ren, Weijiao Yin, Jingxia Li, Junqian Zhang, Ziqi Wang, Manxi Sheng, Bingyi Xu, Liuyan Li, Xiaoyi Liu, Zhihao Lu, Lixin Wan, Fuyou Zhou, Shegan Gao
PURPOSE: This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not...
May 6, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38709986/phase-iii-randomized-placebo-controlled-clinical-trial-of-donepezil-for-treatment-of-cognitive-impairment-in-breast-cancer-survivors-after-adjuvant-chemotherapy-wf-97116
#23
JOURNAL ARTICLE
Stephen R Rapp, Emily V Dressler, W Mark Brown, James L Wade, Nguyet Le-Lindqwister, David King, Kendrith M Rowland, Kathryn E Weaver, Heidi D Klepin, Edward G Shaw, Glenn J Lesser
PURPOSE: To test efficacy of donepezil, a cognitive enhancer, to improve memory in breast cancer survivors who report cancer-related cognitive impairment 1-5 years postchemotherapy. PATIENTS AND METHODS: Adult female BCS exposed to ≥4 cycles of adjuvant chemotherapy 1-5 years before enrollment who reported cancer-related cognitive impairment were eligible. Participants, enrolled at sites affiliated with the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base, were randomly assigned to receive 5 mg of donepezil once daily for 6 weeks titrated to 10 mg once daily for 18 weeks or placebo...
May 6, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38709983/fastoch-feasibility-of-electronic-patient-reported-outcomes-in-older-patients-with-cancer-a-multicenter-prospective-study
#24
JOURNAL ARTICLE
Mathilde Cancel, Carine Sauger, Julie Biogeau, Véronique Dardaine-Giraud, Thierry Lecomte, David Solub, Pierre Combe, Rémy Wilmet, Eugénie Aubard, Amandine Deloigne, Philippe Hébrard, Étienne Dorval
PURPOSE: Multiple studies have demonstrated that electronic patient-reported outcomes (ePROs) improve overall survival and quality of life in cancer care. However, there are no specific prospective data on remote ePRO monitoring in the older population, although they represent a significant proportion of patients with cancer. PATIENTS AND METHODS: From February 2021 to April 2022, patients age 75 years and older under active anticancer treatment were consecutively recruited in six institutions...
May 6, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38701393/neoadjuvant-chemotherapy-in-high-grade-myxoid-liposarcomas-looking-forward-to-what-is-next
#25
LETTER
Brian Schulte, Nicolas Mach, Timothée Olivier
No abstract text is available yet for this article.
May 3, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38701390/minimal-residual-disease-status-in-multiple-myeloma-1-year-after-autologous-hematopoietic-cell-transplantation-and-lenalidomide-maintenance-are-associated-with-long-term-overall-survival
#26
JOURNAL ARTICLE
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario, Alan Howard, Yali Zhang, Claudio Brunstein, Yvonne Efebera, Nancy Geller, Sergio Giralt, Parameswaran Hari, Mary M Horowitz, John Koreth, Amrita Krishnan, Heather Landau, George Somlo, Nina Shah, Edward Stadtmauer, Dan T Vogl, David H Vesole, Philip L McCarthy, Theresa Hahn
PURPOSE: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a three-arm randomized control trial (Blood and Marrow Transplants Clinical Trials Network 0702 Stem Cell Transplant for Myeloma in Combination of Novel Agents [STaMINA]; ClinicalTrials.gov identifier: NCT01109004). METHODS: Four hundred and thirty-five patients consented to the MRD panel, which included 10 monoclonal antibodies measured via six-color MFC...
May 3, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38701389/reply-to-b-schulte-et-al
#27
JOURNAL ARTICLE
Alessandro Gronchi
No abstract text is available yet for this article.
May 3, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38701382/plasma-kidney-injury-molecule-1-for-preoperative-prediction-of-renal-cell-carcinoma-versus-benign-renal-masses-and-association-with-clinical-outcomes
#28
JOURNAL ARTICLE
Wenxin Xu, Valerie Gaborieau, Samuel M Niman, Anush Mukeria, Xiaowen Liu, Krishna P Maremanda, Ayumi Takakura, David Zaridze, Matthew L Freedman, Wanling Xie, David F McDermott, Toni K Choueiri, Paul J Catalano, Venkata Sabbisetti, Joseph V Bonventre, Phillip M Pierorazio, Nirmish Singla, Paul Brennan, Rupal S Bhatt
PURPOSE: Both clear cell and papillary renal cell carcinomas (RCCs) overexpress kidney injury molecule-1 (KIM-1). We investigated whether plasma KIM-1 (pKIM-1) may be a useful risk stratification tool among patients with suspicious renal masses. METHODS: Prenephrectomy pKIM-1 was measured in two independent cohorts of patients with renal masses. Cohort 1, from the prospective K2 trial, included 162 patients found to have clear cell RCC (cases) and 162 patients with benign renal masses (controls)...
May 3, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38691823/elective-pelvic-lymph-node-radiation-therapy-and-the-risk-of-death-in-patients-with-unfavorable-risk-prostate-cancer-a-postrandomization-analysis
#29
JOURNAL ARTICLE
Mutlay Sayan, Ming-Hui Chen, Marian Loffredo, Elizabeth McMahon, Shalini Moningi, Peter F Orio, Paul L Nguyen, Anthony V D'Amico
PURPOSE: Although a contemporary randomized clinical trial has led to the use of whole-pelvic radiation therapy (WPRT), long-term data evaluating a potential reduction in mortality are lacking and are addressed in the current study. MATERIALS AND METHODS: From 2005 to 2015, 350 men with localized, unfavorable-risk prostate cancer (PC) were randomly assigned to receive androgen deprivation therapy (ADT) and RT plus docetaxel versus ADT and RT. Treatment of the pelvic lymph nodes was at the discretion of the treating physician...
May 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38691822/development-and-standardization-of-an-osteoradionecrosis-classification-system-in-head-and-neck-cancer-implementation-of-a-risk-based-model
#30
JOURNAL ARTICLE
Erin E Watson E, Katrina Hueniken, Junhyung Lee, Shao Hui Huang, Amr El Maghrabi, Wei Xu, Amy C Moreno, C Jillian Tsai, Ezra Hahn, Andrew J McPartlin, Christopher M K L Yao, David P Goldstein, John R De Almeida, John N Waldon, Clifton D Fuller, Andrew J Hope, Salvatore L Ruggiero, Michael Glogauer, Ali A Hosni
PURPOSE: Osteoradionecrosis of the jaw (ORN) can manifest in varying severity. The aim of this study is to identify ORN risk factors and develop a novel classification to depict the severity of ORN. METHODS: Consecutive patients with head and neck cancer (HNC) treated with curative-intent intensity-modulated radiation therapy (IMRT) (≥45 Gy) from 2011 to 2017 were included. Occurrence of ORN was identified from in-house prospective dental and clinical databases and charts...
May 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38691821/prevention-and-management-of-osteoradionecrosis-in-patients-with-head-and-neck-cancer-treated-with-radiation-therapy-isoo-mascc-asco-guideline
#31
JOURNAL ARTICLE
Douglas E Peterson, Shlomo A Koyfman, Noam Yarom, Charlotte Duch Lynggaard, Nofisat Ismaila, Lone E Forner, Clifton David Fuller, Yvonne M Mowery, Barbara A Murphy, Erin Watson, David H Yang, Ivan Alajbeg, Paolo Bossi, Michael Fritz, Neal D Futran, Daphna Y Gelblum, Edward King, Salvatore Ruggiero, Derek K Smith, Alessandro Villa, Jonn S Wu, Deborah Saunders
PURPOSE: To provide evidence-based recommendations for prevention and management of osteoradionecrosis (ORN) of the jaw secondary to head and neck radiation therapy in patients with cancer. METHODS: The International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer (ISOO-MASCC) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library databases were searched for randomized controlled trials and observational studies, published between January 1, 2009, and December 1, 2023...
May 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38687953/erratum-adjuvant-abemaciclib-plus-endocrine-therapy-for-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-high-risk-early-breast-cancer-results-from-a-preplanned-monarche-overall-survival-interim-analysis-including-5-year-efficacy
#32
https://read.qxmd.com/read/38687952/erratum-predicting-functional-recovery-and-quality-of-life-in-older-patients-undergoing-colorectal-cancer-surgery-real-world-data-from-the-international-gosafe-study
#33
(no author information available yet)
No abstract text is available yet for this article.
April 30, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38687918/erratum-overall-survival-results-from-the-polo-trial-a-phase-iii-study-of-active-maintenance-olaparib-versus-placebo-for-germline-brca-mutated-metastatic-pancreatic-cancer
#34
(no author information available yet)
No abstract text is available yet for this article.
April 30, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38684039/phase-ib-study-of-unesbulin-ptc596-plus-dacarbazine-for-the-treatment-of-locally-recurrent-unresectable-or-metastatic-relapsed-or-refractory-leiomyosarcoma
#35
JOURNAL ARTICLE
Brian A Van Tine, Matthew A Ingham, Steven Attia, Christian F Meyer, John D Baird, Esther Brooks-Asplund, Dhiren D'Silva, Ronald Kong, Anthony Mwatha, Kylie O'Keefe, Marla Weetall, Robert Spiegel, Gary K Schwartz
PURPOSE: This multicenter, single-arm, open-label, phase Ib study was designed to determine the recommended phase II dose (RP2D) and to evaluate the safety and preliminary efficacy of unesbulin plus dacarbazine (DTIC) in patients with advanced leiomyosarcoma (LMS). PATIENTS AND METHODS: Adult subjects with locally advanced, unresectable or metastatic, relapsed or refractory LMS were treated with escalating doses of unesbulin orally twice per week in combination with DTIC 1,000 mg/m2 intravenously (IV) once every 21 days...
April 29, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38662968/radiation-therapy-with-or-without-cisplatin-for-local-recurrences-of-endometrial-cancer-results-from-an-nrg-oncology-gog-prospective-randomized-multicenter-clinical-trial
#36
JOURNAL ARTICLE
Ann H Klopp, Danielle Enserro, Matthew Powell, Marcus Randall, Julian C Schink, Robert S Mannel, Laura Holman, David Bender, Christina L Kushnir, Floor Backes, Susan L Zweizig, Steven Waggoner, Kristin A Bradley, Lana DeSouza Lawrence, Parviz Hanjani, Christopher J Darus, William Small, Higinia R Cardenes, Jonathan M Feddock, David S Miller
PURPOSE: Pelvic recurrence is a frequent pattern of relapse for women with endometrial cancer. A randomized trial compared progression-free survival (PFS) after treatment with radiation therapy alone as compared with concurrent chemotherapy. MATERIALS AND METHODS: Between February 2008 and August 2020, 165 patients were randomly assigned 1:1 to receive either radiation treatment alone or a combination of chemotherapy and radiation treatment. The primary objective of this study was to determine whether chemoradiation therapy was more effective than radiation therapy alone at improving PFS...
April 25, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38657188/does-duration-of-adverse-events-matter-in-cancer-clinical-trials
#37
LETTER
Sheng Zhang, Wenfeng Li
No abstract text is available yet for this article.
April 24, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38657187/-nectin4-amplification-is-frequent-in-solid-tumors-and-predicts-enfortumab-vedotin-response-in-metastatic-urothelial-cancer
#38
JOURNAL ARTICLE
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E Vera Badillo, J Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein
PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS: We established a NECTIN4 -specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108)...
April 24, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38657186/reply-to-s-zhang-et-al-and-s-selukar
#39
JOURNAL ARTICLE
Nathaniel S O'Connell
No abstract text is available yet for this article.
April 24, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38657182/investigating-the-benefits-of-collecting-low-and-moderate-grade-adverse-events-in-cancer-clinical-trials
#40
LETTER
Subodh Selukar
No abstract text is available yet for this article.
April 24, 2024: Journal of Clinical Oncology
journal
journal
20146
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.